Christopher Rovaldi
CIK 1706040 · Chief Operating Officer · last filed 2025-02-19
Christopher Rovaldi is a Chief Operating Officer who has filed 11 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for KROS, was dated Feb 19, 2025. Across all open-market trades the lifetime net is −$1.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $609.0K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$609.0K
2
11
-$1.43M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KROS | Chief Operating Officer | 60,000 | $10.15 | $609.0K | -$162.0K | 6 | 2025-02-19 |
| ACCELERON PHARMA INC (XLRN) Delisted | SVP, Program Mgmt and Ops | 25,858 | $178.75 | $4.62M | -$1.26M | 5 | 2018-04-04 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-19 | KROS | Grant (A) | +60,000 | $0 | EDGAR |
| 2024-02-15 | KROS | Grant (A) | — | $0 | EDGAR |
| 2023-02-17 | KROS | Grant (A) | — | $0 | EDGAR |
| 2022-04-08 | KROS | Mixed | — | -$84.7K | EDGAR |
| 2022-04-05 | KROS | Mixed | — | -$35.9K | EDGAR |
| 2022-02-03 | KROS | Grant (A) | — | $0 | EDGAR |
| 2018-04-04 | ACCELERON PHARMA INC (XLRN) Delisted | Sell (S) | −3,500 | -$134.4K | EDGAR |
| 2018-03-05 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +4,063 | $0 | EDGAR |
| 2018-01-17 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$229.8K | EDGAR |
| 2018-01-04 | ACCELERON PHARMA INC (XLRN) Delisted | Sell (S) | −2,266 | -$96.1K | EDGAR |